BackgroundFatigue is a frequent and disabling symptom of multiple sclerosis (MS) often associated with impaired quality life (QoL) in patients. Teriflunomide once-daily oral immunomodulator used for the treatment relapsing remitting forms MS. However, its effect on fatigue not well known real practice. We evaluated impact teriflunomide patients MS (RRMS) after 2 years real-world Teri-FAST study...

Multiple sclerosis (MS), a chronic demyelinating neuroinflammatory disease of the central nervous system, is the most common neurological disorder leading to disability in young adulthood. In the last 2 decades, numerous treatments for relapsing-remitting MS have been approved with eleven treatment options available worldwide. One of the determinants in treatment selection is disease activity i...

Given the growing importance of leflunomide in rheumatoid arthritis therapy, it is essential to understand its disposition by considering physiological processes such as CYP enzymes (intestine and liver), transporters (mostly efflux), and systemic conversion (blood). This has led to the development of an impressive semiphysiologically based pharmacokinetic (semi-PBPK) model by Hopkins et al. (“...